Skip to content Skip to footer
Subscribe Now
NEWS

CSL Vifor and Travere Therapeutics’ Filspari (sparsentan) Gains CHMP’s Positive Opinion to Treat IgA Nephropathy  

Shots:  The CHMP has granted positive opinion to CSL (exclusive commercialization rights holder in the EU, Australia & New Zealand) & Travere’s sparsentan for its conditional approval to treat primary IgAN with a urine protein excretion >1.0 g/day. EC’s decision is anticipated in Q2’24 The opinion was supported by the P-III (PROTECT) trial investigating the…
February 23, 2024

Read more

Disease of the Month: IgA Nephropathy
INSIGHTS+

Disease of the Month: IgA Nephropathy

Shots:To create a wholesome environment for the current and the future generation, it’s totally up to life science companies and decision-makers to embrace and integrate every prospect of the underlying disease conditions and address those issues to find curesPharmaShots brings this month an informative take on the disease IgA nephropathyOften known as…
March 13, 2023

Read more

VIEWPOINTS_Dr. Richard Philipson_2023
VIEWPOINTS

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Shots: Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization The interview shows up how Calliditas is…
January 9, 2023

Read more